Stephanie L. Graff, MD

Articles by Stephanie L. Graff, MD

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

ByPaolo Tarantino, MD, PhD,Hope S. Rugo, MD,Guiseppe Curigliano,Joyce O’Shaughnessy, MD,Wolfgang Janni,Komal Jhaveri,Jason Mouabbi,Adam M. Brufsky, MD, PhD,Erika P. Hamilton, MD,Ruth M. O’Regan, Julia Kim,Liz Santarsiero,Murat Akdere,Fen Ye,Henry Owusu,Stephanie L. Graff, MD

June 20th 2025

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

ByStephanie L. Graff, MD,Peter Schmid, MD,Massimo Cristofanilli, MD,David W. Cescon,Tina Hovey,Karson Tse,Petra Vuković,Joyce O’Shaughnessy, MD

August 11th 2024

Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.

ctDNA Assay May Elucidate Outcomes With Chemo in HR+ Breast Cancer

ByStephanie L. Graff, MD

January 4th 2024

Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.

Latest Updated Articles

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database
Published: June 20th 2025 | Updated:

Stephanie L. Graff, MD

Articles by Stephanie L. Graff, MD

26 Risk of Recurrence in Real-World NATALEE- and monarchE-Eligible Populations of Patients With HR+/HER2− Early Breast Cancer in an Electronic Health Record-Derived Database

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

ctDNA Assay May Elucidate Outcomes With Chemo in HR+ Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC

Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups

Nivolumab Sustains DFS Benefits in Muscle-Invasive Urothelial Carcinoma